Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease

Background & Aims: The new name and diagnostic criteria of metabolic-associated fatty liver disease (MAFLD) was proposed in 2020. Although chronic HBV infection has protective effects on lipid profiles and hepatic steatosis, the impact of chronic HBV infection on clinical outcomes of MAFLD r...

Full description

Bibliographic Details
Published in:	JHEP Reports
Main Authors:	Yu-Ming Cheng, Tsung-Han Hsieh, Chia-Chi Wang, Jia-Horng Kao
Format:	Article
Language:	English
Published:	Elsevier 2023-09-01
Subjects:	Hepatic B virus Hepatic steatosis Non-alcoholic liver disease Metabolic associated fatty liver disease Liver fibrosis Atherosclerosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589555923001672

Similar Items

Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome
by: Ma Ai Thanda Han
Published: (2020-09-01)

Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease
by: Kun-Lin Cheng, et al.
Published: (2024-01-01)

Overlapping group between non‐alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research
by: Yu‐Ming Cheng, et al.
Published: (2024-10-01)

Biochemical assessment of metabolic associated fatty liver disease
by: Guerra-Ruiz Armando R., et al.
Published: (2021-03-01)

Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort
by: Wei-Chun Cheng, et al.
Published: (2024-01-01)

Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease
by: Shang-Chin Huang, et al.
Published: (2021-05-01)

The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
by: Francisco Barrera, et al.
Published: (2024-07-01)

Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease
by: Chang-Hai Liu, et al.
Published: (2022-06-01)

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
by: Abdulrahman Ismaiel, et al.
Published: (2022-08-01)

Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease
by: Yamei Duan, et al.
Published: (2022-05-01)

The relationship between diabetes mellitus and non-alcoholic fatty liver disease: a clinical and instrumental paired study
by: Armida N. Sasunova, et al.
Published: (2024-09-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

<b>Analytical methods for evaluation of the fatty acid metabolism in rat liver
by: Eduardo Hideo Gilglioni, et al.
Published: (2018-11-01)

Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease
by: Youwen Tan, et al.
Published: (2024-12-01)

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B—A Retrospective Cohort Study
by: Wang QX, et al.
Published: (2022-08-01)

Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes
by: Georgiana-Diana Cazac, et al.
Published: (2022-09-01)

Alcohol Abstinence Rescues Hepatic Steatosis and Liver Injury via Improving Metabolic Reprogramming in Chronic Alcohol-Fed Mice
by: Aiwen Pi, et al.
Published: (2021-09-01)

What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
by: Giovanni Tarantino, et al.
Published: (2024-02-01)

Corrigendum: Alcohol abstinence rescues hepatic steatosis and liver injury via improving metabolic reprogramming in chronic alcohol-fed mice
by: Aiwen Pi, et al.
Published: (2025-02-01)

Comparison of fatty liver index with fibroscan in non-alcoholic fatty liver disease
by: Marium Ahmed, et al.
Published: (2024-04-01)

Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease
by: Akash Roy, et al.
Published: (2024-09-01)

Assessment of laboratory findings and liver elastography in patients with non-alcoholic fatty liver disease
by: Tarang Taghvaei, et al.
Published: (2023-12-01)

Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
by: Tae Seop Lim, et al.
Published: (2023-07-01)

Advances in non-invasive diagnosis of metabolic dysfunction-associated fatty liver disease
by: WANG Ziqian, et al.
Published: (2024-07-01)

Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
by: Dae Ho Lee
Published: (2020-06-01)

Clinical characteristics of lean metabolic-associated fatty liver disease and the impact of concurrent diabetes mellitus
by: Yu-Ming Cheng, et al.
Published: (2024-09-01)

Adherence to plant based diets reduce the risk of hepatic fibrosis in nonalcoholic fatty liver disease
by: Mahsa Miryan, et al.
Published: (2025-05-01)

Non-Alcoholic Fatty Liver Disease and the Risk of Liver Fibrosis in Chronic Hepatitis B Patients
by: Andri Sanityoso Sulaiman, et al.
Published: (2023-09-01)

Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B
by: Shang-Chin Huang, et al.
Published: (2022-11-01)

Clusters and components of metabolic syndrome (MeS) as a predictor for fatty liver: A cross-sectional study
by: Varanasi Yugandar Bhargav, et al.
Published: (2021-01-01)

The introduction into clinical practice of an algorithm for the diagnosis of liver steatosis in patients with viral pneumonia
by: Taisia A. Turankova, et al.
Published: (2025-01-01)

The validity of serum autotaxin as a predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease
by: Muhammad Abdel-Gawad, et al.
Published: (2023-10-01)

Fatty liver biomarkers and insulin resistance indices in the prediction of non‐alcoholic fatty liver disease in Ghanaian patients
by: A. S. Bockarie, et al.
Published: (2023-11-01)

Polydopamine nanoparticles as a non-pharmaceutical tool in the treatment of fatty liver disease
by: Alessio Carmignani, et al.
Published: (2024-03-01)

Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
by: Jin Won Chang, et al.
Published: (2021-01-01)

Predicting hepatic steatosis degree in metabolic dysfunction-associated steatotic liver disease using obesity and lipid-related indices
by: Paniz Forouzesh, et al.
Published: (2025-03-01)

Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
by: Hye Kyung Hyun, et al.
Published: (2024-03-01)

The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis—Systematic Review and Meta-Analysis
by: Abdulrahman Ismaiel, et al.
Published: (2021-12-01)

Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies
by: Wanghao Liu, et al.
Published: (2024-12-01)

Comparing non-alcoholic fatty liver disease indices in predicting the prevalence and incidence of metabolic syndrome in middle-aged adults
by: Byung Sik Kim, et al.
Published: (2025-03-01)